1. Drug design has evolved from using natural products to more rational approaches using bioinformatics tools. Key steps include identifying disease targets, finding compounds that bind to targets, refining compounds' activity and side effects, and using computer modeling to predict compounds' properties.
2. High-throughput screening allows testing millions of compounds against targets to find initial active compounds. Computational models can then predict additional active compounds and help refine lead compounds.
3. Combinatorial chemistry and large databases of compounds enable creating and testing many compounds in silico and in vitro before animal testing to increase success.
Report
Share
Report
Share
1 of 28
More Related Content
Similar to druggggggggggggggjjjhjgjgygygjhfggfdgfdgdfppt
Bioinformatics plays a key role in drug discovery by enabling researchers to efficiently analyze large amounts of biological data and computationally simulate drug-target interactions. Some important applications of bioinformatics in drug discovery include virtual high-throughput screening of compound libraries against protein targets to identify potential drug leads, analyzing genetic and protein sequences to infer evolutionary relationships and identify drug targets, and using homology modeling to predict the 3D structures of targets to aid in drug design when experimental structures are unknown.
1. Bioinformatics uses computer science and information technology to analyze biological data and assist with drug discovery. It helps identify drug targets and design drug candidates.
2. The drug design process involves identifying a disease target, studying compounds of interest, detecting molecular disease bases, rational drug design, refinement, and testing. Bioinformatics tools assist with each step.
3. CADD uses computational methods to simulate drug-receptor interactions and is heavily dependent on bioinformatics tools and databases. It supports techniques like virtual screening, sequence analysis, homology modeling, and physicochemical modeling to aid drug development.
Intro to in silico drug discovery 2014Lee Larcombe
This document provides an overview of in silico drug design with a focus on safety and efficacy. It discusses using computational approaches to model molecular interactions for small molecule drugs and biologics. For small molecules, it describes obtaining protein structures, simulating binding via docking, and considering absorption and toxicity. For biologics like antibodies, it discusses engineering for reduced immunogenicity and improved half-life via Fc modifications. The goal is developing safer, more effective therapies through computational analysis and protein design.
Drug discovery clinical evaluation of new drugsKedar Bandekar
The document discusses the process of new drug development from initial idea to market launch. It takes 12-15 years and over $1 billion. The process involves identifying a biological target, screening compounds to find hits, optimizing hits to develop leads, and conducting preclinical and clinical trials. Key steps include target identification and validation, high-throughput screening to find initial hits, hit-to-lead and lead optimization processes to improve properties, and three phases of clinical trials to test safety and efficacy in humans. Characteristics of ideal lead compounds include high target affinity and selectivity, drug-like properties, and favorable absorption and toxicity profiles.
Drug discovery clinical evaluation of new drugsKedar Bandekar
The document discusses the process of new drug development from initial idea to market launch. It takes 12-15 years and over $1 billion. The process involves identifying a biological target, screening compounds to find hits, optimizing hits to develop leads, and conducting preclinical and clinical trials. Key steps include target identification and validation, high-throughput screening to find initial hits, hit-to-lead and lead optimization processes to improve properties, and progression through preclinical and clinical phases of drug development. Characteristics of ideal lead compounds include high target affinity and selectivity, efficacy, appropriate physicochemical properties, and favorable ADME profile.
Bioinformatics is the application of computer science and information technology to the field of biology and healthcare. It involves storing, organizing, and analyzing large amounts of biological data, such as DNA sequences and protein structures. Some key goals of bioinformatics include understanding normal biological processes, diseases, and improving drug discovery through computational analysis of various types of biological data, including sequences, structures, and scientific literature.
Computer Aided Drug Design uses computational methods to help streamline the drug discovery process. Key steps include identifying drug targets, generating molecular structures, evaluating interactions between potential drug compounds and targets through docking simulations, and developing quantitative structure-activity relationship (QSAR) models to predict compound activity and guide synthetic efforts. The overall goal is to reduce the cost and time needed to develop new pharmaceutical agents in a rational, mechanism-based manner.
This document discusses computational aided drug design. It begins by defining drug and the drug design process. It describes that the selected drug molecule should be an organic small molecule that is complementary in shape and oppositely charged to the target biomolecule. It then discusses ligand based and structure based drug design approaches. Various techniques used in drug design are also summarized such as x-ray crystallography, NMR, homology modeling, and computer aided drug design. Benefits of computational aided drug design include streamlining drug discovery, eliminating compounds with undesirable properties, and identifying and optimizing new drugs in a time and cost effective manner.
In silico drug designing is the drug design which can be carried out in silicon chip,i.e., within computers. The slides are helpful to know a brief description about in silico drug designing.
Computer aided drug design (CADD) uses computer modeling to help design and discover new drug molecules. It involves designing molecules that are complementary in shape and charge to bind to a biomolecular target like a protein. This can help drugs activate or inhibit the target to produce therapeutic effects. CADD is not a direct route to new drugs but provides information to guide and coordinate drug discovery experiments in a more efficient manner. It is hoped CADD can help save time and money in the drug development process.
This document summarizes different levels of computer simulations used in pharmacokinetics and pharmacodynamics:
1. Level 1 involves simulating the whole organism using systems of differential equations to model pharmacokinetic-pharmacodynamic relationships. These models can generate synthetic clinical trial data.
2. Level 2 simulates isolated tissues and organs using more detailed distributed parameter models to better represent physiological processes than lumped parameter whole-body models.
3. Level 3 simulates cells using complex models of intracellular processes, signaling networks, and membrane transport, though cellular mechanisms are still not fully known.
4. Level 4 involves computational design of proteins and genes, with the challenge of integrating information across multiple structural levels
Drug Discovery subject (clinical research)Jannat985397
The document discusses various topics related to drug discovery including methods of target validation, combinatorial chemistry, quantitative structure-activity relationship analysis, and computer-aided drug design. It describes the multi-step process of drug discovery from identifying potential drug targets to optimizing lead compounds and outlines the steps of pre-clinical and clinical drug testing required for regulatory approval. Key aspects covered include high-throughput screening techniques used to identify hits from compound libraries as well as tools for drug design like solid phase synthesis and parallel synthesis.
Computational Drug Discovery: Machine Learning for Making Sense of Big Data i...Chanin Nantasenamat
In this lecture, I provide an overview on how computers can be instrumental in drug discovery efforts. Topics covered includes: big data as a result of omics effort; bioinformatics; cheminformatics; biological space; chemical space; how computers particularly machine learning (and data science) can be applied in the context of drug discovery.
A video of this lecture is also provided on the "Data Professor" YouTube channel available at http://bit.ly/dataprofessor
If you are fascinated about data science, it would mean the world to me if you would consider subscribing to this channel (by clicking the link below):
http://bit.ly/dataprofessor
This document provides an overview of genomics, bioinformatics, and related topics. It discusses:
- The genomics and bioinformatics group members Amit Garg, Lokesh Joshi, and Pankaj Phogat.
- Definitions of genomics, genome, and bioinformatics.
- An overview of the human genome project including its history, goals of identifying and sequencing all human genes, and completion in 2003.
- Other completed genome projects such as for bacteria and yeast.
- The role of bioinformatics in collecting, organizing, analyzing, and sharing biological data through computational modeling, databases, and other tools.
Bioinformatics: Building the cornerstones of Sequence Homology and its use fo...OECD Environment
24 June 2019: This OECD seminar presented and discussed the potential use of genome sequence, bioinformatic tools and databases in a regulatory decision process for microbial pesticides.
In silico drug design uses computer simulation and modeling to aid the drug discovery process. There are two main approaches: ligand-based drug design which relies on knowledge of molecules that bind to the target, and structure-based drug design which uses the 3D structure of the target. The basic steps are to select a disease target, validate the target, determine the target structure, screen compound libraries through docking simulations to identify potential drug leads, optimize lead compounds, and progress to preclinical and clinical testing. In silico methods help eliminate compounds that may have toxicity or interaction issues early in the discovery process.
This document discusses various topics related to drug discovery through bioinformatics. It begins by describing how genome-wide RNAi screening in the nematode C. elegans can be used to identify genes involved in biological pathways related to diseases like type-2 diabetes. It then discusses topics like structural genomics, target identification and validation, high-throughput screening approaches and facilities, sources for screening libraries, criteria for hit and lead compounds, and computational methods used in hit identification and optimization like pharmacophore modeling and evaluating compounds against the "rule of five". Descriptors that can be used for characterizing compounds are also listed.
This document discusses clustering the temporal sequences of 3D protein structures. It proposes extracting features from molecular dynamics simulations using wavelet transforms to capture protein motion, rather than just structure. Singular value decomposition is used to analyze spatial and frequency motions. Affinity propagation clustering groups similar spatial motions and frequency patterns into clusters. Future work includes examining collective motions, relationships between motions, and using the analysis for flexibility docking simulations.
The document describes a study that aimed to identify potential novel inhibitors for the nsP2 protease of the Chikungunya virus (CHIKV) through computational methods. Specifically, the study used homology modeling to generate a 3D model of the nsP2 protease. Potential binding sites were predicted and a library of compounds was screened through molecular docking simulations. The best scoring compound, LIGAND_4, was identified as a promising antiviral candidate that binds efficiently to the nsP2 protease target. Future work could include QSAR studies to optimize LIGAND_4 and experimental validation.
This document discusses curcumin and curcumin analogs as potential anti-cancer agents. It first provides background on curcumin, noting that it is the main constituent in turmeric and has demonstrated antioxidant and anti-cancer properties. It then describes several synthetic methods that have been used to produce curcumin analogs, with modified chemical structures. Several curcumin analogs are presented that were synthesized using these methods. The document discusses in vitro tests of the antioxidant and anti-cancer effects of curcumin and its analogs, including their ability to inhibit tubulin polymerization. It concludes that the synthetic analogs demonstrated improved antioxidant and anti-cancer activity compared to curcumin itself, with effects related to their
1. The document describes AUTODOCK, an automated docking software used to predict optimal protein-ligand interactions. It summarizes key search algorithms like simulated annealing and genetic algorithms.
2. As an example application, the document uses AUTODOCK to dock the ligand AHA006 to the HIV-1 protease protein. It describes the preparation steps including assigning charges and defining rotatable bonds.
3. The docking is run using simulated annealing, generating 100 different clusters ranging widely in energy. The lowest energy conformation is not close to the original position, but a higher energy conformation is closest to the original.
This document discusses molecular docking techniques. It describes two main tasks of docking tools: sampling conformational ligand space and scoring protein-ligand complexes. It outlines early rigid-body docking approaches and introduces flexibility through methods like Monte Carlo, molecular dynamics, and genetic algorithms. It also discusses fragment-based docking and techniques for placing fragments and rigid molecules like geometric hashing, pose clustering, and clique detection. The document compares scoring functions including shape complementarity, empirical, force field, knowledge-based, and consensus scoring. It notes that while docking reliability is limited, it can provide new suggestions and that consensus scoring may reduce false positives.
Protection and referral for CBP members.pptMohammed Nizam
Protection in humanitarian responses is very important· and it is heart· of all humanitarian activities . Effective referral· through updated referral· pathways is vital for protection· responses . To ensure· community· resilience for protection· risk· mitigation and prevention· , capacity-building on referral· pathways is essential· .
The slides for this topic· helps you to guide· some basic knowledge· to teach· CBP members on that.
As we reflect on our inaugural year at BacharLorai, we celebrate our efforts toward achieving our vision of a world where every Bangladeshi has access to the resources and opportunities needed to thrive. Thanks to our dedicated team and supportive community, we have made significant strides in empowering Bangladeshis worldwide. We've directly impacted over 1,400 lives through diverse, innovative initiatives aimed at addressing crucial societal needs.
SDG Stocktake Georgia 2024 - SDGs Through the Eyes of Georgia's Business SectorUNGlobalCompactNetwo1
SDGs Through the Eyes of Georgia's Business Sector. The research was carried out by the UN Global Compact Network Georgia in partnership with EY Georgia, funding was provided by Sweden.
Presentation by R. Derek Trunkey, an analyst in CBO’s National Security Division, at the 2024 Conference of the Western Economic Association International.
The FY2025 Proposed Budget Report provides a comprehensive overview of the financial plan for the upcoming fiscal year for the City of Winter Springs. It outlines the city's revenue sources, expenditure plans, and fiscal policies, emphasizing transparency and fiscal responsibility. Key highlights include:
A total proposed budget of approximately $68.3 million, representing a 6% decrease from the prior fiscal year.
A focus on balancing economic growth with environmental conservation, reflecting the city's commitment to maintaining high-quality government services and public infrastructure.
Detailed breakdowns of budget allocations across various departments, including General Fund, Enterprise Funds, and other governmental funds.
An Executive Summary that reviews the financial outlook, funding sources, expenditure highlights, and personnel costs.
Specific budgetary considerations for major projects, capital outlay, debt service, and interfund transfers.
Projections of changes in fund balance and equity for governmental and enterprise funds, ensuring fiscal sustainability and sound financial management.
The report also discusses challenges faced by the city, such as inflation, infrastructure maintenance, and the need for strategic investments in public services and facilities. It includes detailed appendices with financial data, organizational charts, and a glossary of terms. This document serves as a crucial tool for city officials, stakeholders, and residents to understand and engage with the city's financial planning and priorities for FY2025.
This presentation by Ivan Sergejev from the Estonian Ministry of Finance was part of the Expert Exchange "Youth Empowerment for a Just Energy Transition" held on June 18, 2024.
Presentation by Edward G. Keating, CBO’s Deputy Director of National Security, at the 2024 Conference of the Western Economic Association International.
Declines in Availability of Super Hornet Fighter Aircraft
druggggggggggggggjjjhjgjgygygjhfggfdgfdgdfppt
1. Important Points in Drug Design based on
Bioinformatics Tools
History of Drug/Vaccine development
– Plants or Natural Product
• Plant and Natural products were source for medical substance
• Example: foxglove used to treat congestive heart failure
• Foxglove contain digitalis and cardiotonic glycoside
• Identification of active component
– Accidental Observations
• Penicillin is one good example
• Alexander Fleming observed the effect of mold
• Mold(Penicillium) produce substance penicillin
• Discovery of penicillin lead to large scale screening
• Soil micoorganism were grown and tested
• Streptomycin, neomycin, gentamicin, tetracyclines etc.
http://www.geocities.com/bioinformaticsweb/drugdiscovery.html
2. Important Points in Drug Design based on
Bioinformatics Tools
• Chemical Modification of Known Drugs
– Drug improvement by chemical modification
– Pencillin G -> Methicillin; morphine->nalorphine
• Receptor Based drug design
– Receptor is the target (usually a protein)
– Drug molecule binds to cause biological effects
– It is also called lock and key system
– Structure determination of receptor is important
• Ligand-based drug design
– Search a lead ocompound or active ligand
– Structure of ligand guide the drug design process
3. Important Points in Drug Design based on
Bioinformatics Tools
• Identify Target Disease
– Identify and study the lead compounds
– Marginally useful and may have severe side effects
• Refinement of the chemical structures
– Detect the Molecular Bases for Disease
– Detection of drug binding site
– Tailor drug to bind at that site
– Protein modeling techniques
– Traditional Method (brute force testing)
10. Important Points in Drug Design based on
Bioinformatics Tools
• Application of Genome
– 3 billion bases pair
– 30,000 unique genes
– Any gene may be a potential drug target
– ~500 unique target
– Their may be 10 to 100 variants at each target gene
– 1.4 million SNP
– 10200 potential small molecules
11. Important Points in Drug Design based on
Bioinformatics Tools
• Detect the Molecular Bases for Disease
– Detection of drug binding site
– Tailor drug to bind at that site
– Protein modeling techniques
– Traditional Method (brute force testing)
• Rational drug design techniques
– Screen likely compounds built
– Modeling large number of compounds (automated)
– Application of Artificial intelligence
– Limitation of known structures
12. Important Points in Drug Design based on
Bioinformatics Tools
• Refinement of compounds
– Refine lead compounds using laboratory techniques
– Greater drug activity and fewer side effects
– Compute change required to design better drug
• Quantitative Structure Activity Relationships (QSAR)
– Compute functional group in compound
– QSAR compute every possible number
– Enormous curve fitting to identify drug activity
– chemical modifications for synthesis and testing.
• Solubility of Molecule
• Drug Testing
13. Drug Discovery & Development
Identify disease
Isolate protein
involved in
disease (2-5 years)
Find a drug effective
against disease protein
(2-5 years)
Preclinical testing
(1-3 years)
Formulation
Human clinical trials
(2-10 years)
Scale-up
FDA approval
(2-3 years)
14. Techology is impacting this process
Identify disease
Isolate protein
Find drug
Preclinical testing
GENOMICS, PROTEOMICS & BIOPHARM.
HIGH THROUGHPUT SCREENING
MOLECULAR MODELING
VIRTUAL SCREENING
COMBINATORIAL CHEMISTRY
IN VITRO & IN SILICO ADME MODELS
Potentially producing many more targets
and “personalized” targets
Screening up to 100,000 compounds a
day for activity against a target protein
Using a computer to
predict activity
Rapidly producing vast numbers
of compounds
Computer graphics & models help improve activity
Tissue and computer models begin to replace animal testing
15. 1. Gene Chips
• “Gene chips” allow us
to look for changes in
protein expression for
different people with a
variety of conditions,
and to see if the
presence of drugs
changes that expression
• Makes possible the
design of drugs to
target different
phenotypes
compounds administered
people / conditions
e.g. obese, cancer,
caucasian
expression profile
(screen for 35,000 genes)
16. Biopharmaceuticals
• Drugs based on proteins, peptides or natural
products instead of small molecules (chemistry)
• Pioneered by biotechnology companies
• Biopharmaceuticals can be quicker to discover
than traditional small-molecule therapies
• Biotechs now paring up with major
pharmaceutical companies
17. 2. High-Throughput Screening
Screening perhaps millions of compounds in a corporate
collection to see if any show activity against a certain disease
protein
18. High-Throughput Screening
• Drug companies now have millions of samples of
chemical compounds
• High-throughput screening can test 100,000
compounds a day for activity against a protein target
• Maybe tens of thousands of these compounds will
show some activity for the protei
• The chemist needs to intelligently select the 2 - 3
classes of compounds that show the most promise for
being drugs to follow-up
19. Informatics Implications
• Need to be able to store chemical structure and biological data for
millions of datapoints
– Computational representation of 2D structure
• Need to be able to organize thousands of active compounds into
meaningful groups
– Group similar structures together and relate to activity
• Need to learn as much information as possible from the data (data
mining)
– Apply statistical methods to the structures and related information
20. 3. Computational Models of Activity
• Machine Learning Methods
– E.g. Neural nets, Bayesian nets, SVMs, Kahonen nets
– Train with compounds of known activity
– Predict activity of “unknown” compounds
• Scoring methods
– Profile compounds based on properties related to target
• Fast Docking
– Rapidly “dock” 3D representations of molecules into 3D
representations of proteins, and score according to how well
they bind
21. 4. Combinatorial Chemistry
• By combining molecular “building blocks”, we
can create very large numbers of different
molecules very quickly.
• Usually involves a “scaffold” molecule, and sets
of compounds which can be reacted with the
scaffold to place different structures on
“attachment points”.
22. Combinatorial Chemistry Issues
• Which R-groups to choose
• Which libraries to make
– “Fill out” existing compound collection?
– Targeted to a particular protein?
– As many compounds as possible?
• Computational profiling of libraries can help
– “Virtual libraries” can be assessed on computer
23. 5. Molecular Modeling
• 3D Visualization of interactions between compounds and proteins
• “Docking” compounds into proteins computationally
24. 3D Visualization
• X-ray crystallography and NMR Spectroscopy can
reveal 3D structure of protein and bound
compounds
• Visualization of these “complexes” of proteins and
potential drugs can help scientists understand the
mechanism of action of the drug and to improve
the design of a drug
• Visualization uses computational “ball and stick”
model of atoms and bonds, as well as surfaces
• Stereoscopic visualization available
26. 6. In Vitro & In Silico ADME
models
• Traditionally, animals were used for pre-human testing.
However, animal tests are expensive, time consuming and
ethically undesirable
• ADME (Absorbtion, Distribution, Metabolism, Excretion)
techniques help model how the drug will likely act in the
body
• These methods can be experemental (in vitro) using
cellular tissue, or in silico, using computational models
27. In Silico ADME Models
• Computational methods can predict compound
properties important to ADME, e.g.
– LogP, a liphophilicity measure
– Solubility
– Permeability
– Cytochrome p450 metabolism
• Means estimates can be made for millions of
compouds, helping reduce “atrittion” – the failure
rate of compounds in late stage
28. Size of databases
• Millions of entries in databases
– CAS : 23 million
– GeneBank : 5 million
• Total number of drugs worldwide: 60,000
• Fewer than 500 characterized molecular
targets
• Potential targets : 5,000-10,000